DENTSPLY SIRONA Inc. Common Stock (XRAY)
Stock · NASDAQ · Health Care
$8.57as of 10/16/2026
Price chart
XRAY Signal Track Record
How signals performed across all stocks →What XRAY's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 35 | -2.4% | 40% | September 1, 2026 |
| Bollinger Band Breakdown | 25 | -3.6% | 32% | September 15, 2026 |
| Bollinger Band Breakout | 20 | -2.5% | 40% | July 15, 2026 |
| 200-Day Moving Average TouchActive now | 5 | -4.9% | 40% | July 2, 2026 |
| Any 20-session window (baseline) | -2.6% | 41% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About XRAY
DENTSPLY SIRONA Inc. develops, manufactures, and markets dental equipment supported by cloud-enabled solutions, dental products, and healthcare consumable products in urology and enterology worldwide. It operates through four segments: Connected Technology Solutions, Essential Dental Solutions, Orthodontic and Implant Solutions, and Wellspect Healthcare. The Connected Technology Solutions segment offers imaging equip…
- Sector
- Health Care
- Industry
- Medical/Dental Instruments
- Employees
- 14,000
- Website
- www.dentsplysirona.com/
Fundamentals
- 1-day range
- $9.74$10
- Market cap
- $2.64B
- P/E (trailing)
- —
- P/E (forward)
- 6.49
- EPS (trailing)
- $-2.74
- Dividend yield
- 5.50%
- Beta
- 0.88
- Avg. volume
- 5.10M
- Ex-dividend date
- December 26, 2025
- Dividend pay date
- January 9, 2026
How DENTSPLY SIRONA Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 26, 2026 · via SEC EDGAR / Finnhub
Forecasts
16 analyst ratings
DENTSPLY SIRONA Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- XRAYDENTSPLY SIRONA Inc. Common Stock$8.57▼ 2.94%Market cap $2.64BP/E —$8.38$14.76
- PLSEPulse Biosciences Inc Common Stock (DE)$44.43▼ 2.54%Market cap $2.65BP/E —$12.56$58.9
- UFPTUFP Technologies Inc. Common Stock$291.67▼ 1.86%Market cap $2.41BP/E 31.50$173.86$338.71
- HTFLHeartflow Inc. Common Stock$48.29▼ 5.14%Market cap $2.34BP/E —$20.13$54.32
- ATRCAtriCure Inc. Common Stock$56.07▼ 2.96%Market cap $2.01BP/E 261.42$25.36$61.7
- LMATLeMaitre Vascular Inc. Common Stock$80.82▼ 2.81%Market cap $1.85BP/E 29.17$78.22$118.01
- NVCRNovoCure Limited Ordinary Shares$14.07▼ 2.36%Market cap $1.83BP/E —$9.82$21.45
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| XRAY DENTSPLY SIRONA Inc. Common Stock | $2.64B | — | $8.57 | ▼ 2.94% | $8.38$14.76 |
| PLSE Pulse Biosciences Inc Common Stock (DE) | $2.65B | — | $44.43 | ▼ 2.54% | $12.56$58.9 |
| UFPT UFP Technologies Inc. Common Stock | $2.41B | 31.50 | $291.67 | ▼ 1.86% | $173.86$338.71 |
| HTFL Heartflow Inc. Common Stock | $2.34B | — | $48.29 | ▼ 5.14% | $20.13$54.32 |
| ATRC AtriCure Inc. Common Stock | $2.01B | 261.42 | $56.07 | ▼ 2.96% | $25.36$61.7 |
| LMAT LeMaitre Vascular Inc. Common Stock | $1.85B | 29.17 | $80.82 | ▼ 2.81% | $78.22$118.01 |
| NVCR NovoCure Limited Ordinary Shares | $1.83B | — | $14.07 | ▼ 2.36% | $9.82$21.45 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Reasons to Retain DENTSPLY SIRONA Stock in Your Portfolio for NowYahoo · 9/17/2026
- BMO Capital Maintains Market Perform on Dentsply Sirona, Lowers Price Target to $10Benzinga · 9/17/2026
- 3 Russell 2000 Stocks We Steer Clear OfYahoo · 9/11/2026
Insider Activity
Insider Actions →- John C. Fortson · August 10, 2026 · Grant104.2K
- John C. Fortson · August 10, 2026 · Grant24.0K
- Andrea L. Frohning · August 7, 2026 · Tax Withholding802 @ $12.12
- Jonathan Jay Mazelsky · June 30, 2026 · Grant2.8K @ $10.56
- Clyde Hosein · June 15, 2026 · Buy6.5K @ $9.99
- Brian T. Gladden · June 15, 2026 · Buy10.0K @ $10.02
- Jonathan Jay Mazelsky · June 12, 2026 · Grant10.0K @ $10.14
- Brian P. McKeon · June 12, 2026 · Buy10.0K @ $10.12
- Michael J. Barber · June 11, 2026 · Buy15.2K @ $9.89
- Betsy D. Holden · June 11, 2026 · Buy10.1K @ $9.88
- Michael J. Barber · June 3, 2026 · Grant22.8K
- Janet S. Vergis · June 3, 2026 · Grant22.8K
- Jonathan Jay Mazelsky · June 3, 2026 · Grant22.8K
- James D. Forbes · June 3, 2026 · Grant28.9K
- Brian T. Gladden · June 3, 2026 · Grant22.8K
Institutional Ownership
March 31, 2026
- Total shares held
- 201.39M
- Total value held
- $2.32B
- Institutional holders
- 371
- Unknown19.25M
- Unknown15.13M
- Unknown12.79M
- Unknown10.00M
- Unknown9.00M
- Unknown7.80M
- Unknown7.24M
- Unknown6.72M
- Unknown6.39M
- Unknown4.51M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 11, 2026
XRAY: Earnings, Target Cut, Expansion, Medicare Coverage
XRAY reported its Q2 earnings, prompting analysts to review the company’s outlook. Piper Sandler lowered its target to $12, citing the reset strategy after a new Midwest dental partnership. Meanwhile, the Wellspect unit announced Medicare reimbursement for its Surity urinary portfolio, expanding the company’s product reach. These developments add new layers to XRAY’s growth narrative.
XRAY: Earnings, Target Cut, Expansion, Medicare Coverage. XRAY reported its Q2 earnings, prompting analysts to review the company’s outlook. Piper Sandler lowered its target to $12, citing the reset strategy after a new Midwest dental partnership. Meanwhile, the Wellspect unit announced Medicare reimbursement for its Surity urinary portfolio, expanding the company’s product reach. These developments add new layers to XRAY’s growth narrative.